This HTML5 document contains 75 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00735/identifier/pharmgkb/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00735/identifier/wikipedia/
n9http://linked.opendata.cz/resource/AHFS/
n16http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n10http://linked.opendata.cz/resource/drugbank/dosage/
n19http://linked.opendata.cz/resource/drugbank/mixture/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00735/identifier/kegg-compound/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00735/identifier/pubchem-compound/
n27http://bio2rdf.org/drugbank:
n18http://linked.opendata.cz/resource/drugbank/drug/DB00735/identifier/pubchem-substance/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00735/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n21http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00735/identifier/national-drug-code-directory/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n26http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n8http://www.drugs.com/cdi/
n23http://www.rxlist.com/cgi/generic2/
n4http://linked.opendata.cz/resource/drugbank/property/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00735/identifier/chemspider/
xsdhhttp://www.w3.org/2001/XMLSchema#
n6http://linked.opendata.cz/resource/atc/
n5http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00735
rdf:type
n3:Drug
n3:description
Naftifine is a synthetic, broad spectrum, antifungal agent and allylamine derivative for the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans and Epidermophyton floccosum.
n3:dosage
n10:271B5253-363D-11E5-9242-09173F13E4C5 n10:271B5254-363D-11E5-9242-09173F13E4C5 n10:271B5255-363D-11E5-9242-09173F13E4C5 n10:271B5256-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
Approximately 2 to 3 days following topical administration.
n3:indication
For the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms <i>Trichophyton rubrum</i>, <i>Trichophyton mentagrophytes</i>, <i>Trichophyton tonsurans</i> and <i>Epidermophyton floccosum</i>.
n3:manufacturer
n16:271B524A-363D-11E5-9242-09173F13E4C5
owl:sameAs
n21:DB00735 n27:DB00735
dcterms:title
Naftifine
adms:identifier
n12:DB00735 n13:66071 n14:47641 n15:C08071 n17:0259-4770-40 n18:46504777 n24:PA164748617 n25:Naftifine
n3:mechanismOfAction
Although the exact mechanism of action against fungi is not known, naftifine appears to interfere with sterol biosynthesis by inhibiting the enzyme squalene 2,3-epoxidase. This inhibition of enzyme activity results in decreased amounts of sterols, especially ergosterol, and a corresponding accumulation of squalene in the cells.
n3:packager
n16:271B5247-363D-11E5-9242-09173F13E4C5 n16:271B5248-363D-11E5-9242-09173F13E4C5 n16:271B5249-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Naftifine and/or its metabolites are excreted via the urine and feces with a half-life of approximately two to three days.
n3:synonym
Naftifinum Naftifin Naftifina Naftin Naftifine
n5:hasAHFSCode
n9:84-04-08-04
n3:mixture
n19:271B5246-363D-11E5-9242-09173F13E4C5
n3:salt
n3:synthesisReference
"DrugSyn.org":http://www.drugsyn.org/Naftifine.htm
foaf:page
n8:naftifine-cream.html n23:naft.htm
n3:IUPAC-Name
n4:271B525B-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5261-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5260-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B525D-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B525E-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B525F-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5259-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B525A-363D-11E5-9242-09173F13E4C5 n4:271B5257-363D-11E5-9242-09173F13E4C5 n4:271B5270-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5258-363D-11E5-9242-09173F13E4C5
n5:hasATCCode
n6:D01AE22
n3:H-Bond-Acceptor-Count
n4:271B5267-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5268-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5262-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5263-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5265-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5264-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5266-363D-11E5-9242-09173F13E4C5
n3:absorption
Following single topical applications of 3H-labeled naftifine gel 1% to the skin of healthy subjects, up to 4.2% of the applied dose was absorbed.
n3:affectedOrganism
Yeast and other fungi
n3:casRegistryNumber
65472-88-0
n3:containedIn
n26:271B5252-363D-11E5-9242-09173F13E4C5 n26:271B5250-363D-11E5-9242-09173F13E4C5 n26:271B5251-363D-11E5-9242-09173F13E4C5 n26:271B524E-363D-11E5-9242-09173F13E4C5 n26:271B524F-363D-11E5-9242-09173F13E4C5 n26:271B524C-363D-11E5-9242-09173F13E4C5 n26:271B524D-363D-11E5-9242-09173F13E4C5 n26:271B524B-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B526C-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B526E-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B526F-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B526B-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B526A-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B526D-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B525C-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5269-363D-11E5-9242-09173F13E4C5